Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/42—One nitrogen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P3/00—Drugs for disorders of the metabolism
  • A61P3/06—Antihyperlipidemics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• the present invention relates to a process for the preparation of amorphous rosuvastatin calcium, substantially free of alkali metal impurities, via ammonium salts of rosuvastatin as intermediary compounds.
• Rosuvastatin is generic name for (+)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N- methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-heptenoic acid administered in the therapy as its calcium salt as commercial drug, and illustrated in Formula 1 hereinafter, which compound is an inhibitor of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG CoA reductase), useful in the treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis.
• HMG CoA reductase 3-hydroxy-3-methylglutaryl-coenzyme A reductase
• WO 2005/023778 describes a process for the preparation of rosuvastatin calcium by conversion of C 1 to C 4 alkyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin with a base, preferably sodium hydroxide, in the presence of a C 1 to C 4 alcohol, preferably ethanol, to a solution of rosuvastatin salt, e.g. its sodium salt and converted said salt into rosuvastatin calcium by adding a source of calcium to said solution.
• a base preferably sodium hydroxide
• a novel crystalline form of rosuvastatin calcium can be prepared by crystallization of amorphous form of rosuvastatin calcium from a mixture of: (i) water and acetonitrile in the ratio of 1 : 1 by volume; (ii) water and acetone in the ratio of 1 : 1 by volume; or water, methanol and methyl terf-butyl ether in the ratio of 1:1 :1 by volume, what is described in WO 2000/042024.
• WO 01/60804 discloses certain novel amine salt with rosuvastatin, which may be prepared by addition of an appropriate amine or base to a solution of rosuvastatin acid in acetonitrile or ethyl acetate.
• Certain novel amine salts of rosuvastatin may be used in the preparation of amorphous calcium salt of rosuvastatin, which process comprises sequential reaction of the crystalline methylammonium salt of rosuvastatin with sodium hydroxide, followed by a water soluble calcium salt, such as calcium chloride, under aqueous conditions.
• amorphous calcium salt of rosuvastatin which process comprises sequential reaction of the crystalline methylammonium salt of rosuvastatin with sodium hydroxide, followed by a water soluble calcium salt, such as calcium chloride, under aqueous conditions.
• An approach is disclosed in WO 2005/051921 where rosuvastatin calcium salt is purified by conversion into isopropylammonium or cyclohexylammonium salt and back to calcium salt.
• a pure amorphous form of rosuvastatin calcium of Formula 1 having a purity of more than 99.5%, preferably a purity of more than 99.8%, more preferably a purity of more than 99.9% as determined by HPLC area percentage, and free from any traces of alkali metal impurities.
• the present invention provides a process for producing pure amorphous calcium salt of rosuvastatin, substantially free of alkali metal impurities, e.g. sodium cation impurity, which comprises:
• the starting ester may be methyl ester of rosuvastatin, preferably terf-butyl ester of rosuvastatin (tert-butyl rosuvastatin).
• An organic nitrogen base is selected from the group consisting of guanidines, amidines, amines, quaternary ammonium hydroxides, unsubstituted or C 1 to C 6 alkyl substituted piperazines, morpholines, thiomorpholines, imidazolidines or adamantans.
• Any aprotic solvent in step a) may be used, preferably tetrahydrofuran.
• Any appropriate source of calcium may be used, preferably calcium chloride, calcium hydroxide, calcium acetate and calcium palmitate.
• the process according to the invention may be performed in a solutions of an intermediary salts of rosuvastatin with organic nitrogen bases.
• Said salts are novel compounds, e.g. amine salts of rosuvastatin, not described in the prior art.
• rosuvastatin salts of an organic nitrogen bases may be isolated, optionally purified, e.g. by recrystallization, and used as intermediates in the preparation of the pure amorphous rosuvastatin calcium salt.
• the desired pure amorphous rosuvastatin calcium salt is substantially free from any traces of alkali metal salt impurities, e.g. from sodium cation, containing in intermediary rosuvastatin sodium salt obtained according to prior art processes.
• Amorphous rosuvastatin calcium prepared by the process according to the invention has at least 99.5% of chromatographic purity; moreover when using very pure starting C 1 to C 5 rosuvastatin ester more than 99.8% purity, even more, in some cases more than 99.9% of chromatographic purity of desired rosuvastatin calcium may be obtained.
• chromatographic purity means purity as determined by area percentage HPLC ("High Pressure Liquid Chromatography").
• the amorphous rosuvastatin calcium may be prepared by conversion of the novel intermediary ammonium salts of rosuvastatin with the source of calcium.
• Intermediary ammonium salts of rosuvastatin may be obtained by contacting rosuvastatin free acid with an appropriate amine according to the procedure which comprises:
• the water immiscible solvent used in above steps b) and d) is selected from the group consisting of C 2 to C 5 alkyl esters, e.g. acetate esters, preferably ethyl acetate (AcOEt), iso- propyl acetate (i-Pr acetate) and /so-butyl acetate, ethers, chlorinated hydrocarbons and cyclic hydrocarbons.
• acetate esters e.g. acetate esters, preferably ethyl acetate (AcOEt), iso- propyl acetate (i-Pr acetate) and /so-butyl acetate, ethers, chlorinated hydrocarbons and cyclic hydrocarbons.
• acid for acidifying aqueous solution of rosuvastatin alkali salt in step c) of above process e.g. hydrochloric acid or phosphoric acid may be used.
• rosuvastatinic acid (rosuvastatin free acid) means (+)-7-[4-(4-fluorophenyl)-6- isopropyl-2-(N-methyl-N-methylsulfonylamino)pyrimidin-5-yl]-(3R,5S)-dihydroxy-(E)-6- heptenoic acid.
• step a) for cleavage of starting rosuvastatin esters according to above procedure
• purification and isolation of various isolable intermediary rosuvastatin salts with an appropriate amine may be performed after which the content of sodium cation impurity may be lowered, e.g. by washing the reaction mixture of step b) by water immiscible solvents, in the desired rosuvastatin calcium salt to less than 0.1 % of sodium by weight.
• novel ammonium salts of rosuvastatin were prepared in well defined forms, preferably as terf-octylammonium salt of rosuvastatin, which may be isolated in highly pure crystalline form and may be valuable as analytical standard for HPLC and other analyses.
• a pharmaceutical formulation comprising rosuvastatin calcium prepared according to above described process and a method of treatment of hyperlipidemia, hypercholesterolemia and atherosclerosis, comprising the step of administering said pharmaceutical formulation to the mammal in need thereof.
• An object of the present invention is to find a novel process for the preparation of pure amorphous rosuvastatin calcium, substantially free of sodium cation impurities or other alkali metal cation impurities and other impurities as well, which would avoid the use of alcohols, e.g. Ci to C 4 alcohols as a reaction medium and the use of alkali metal hydroxides, e.g. sodium hydroxide, thus eliminating O-alkyl rosuvastatin impurities (see Scheme 1), e.g.
• the term “substantially free” means that the desired obtained amorphous rosuvastatin calcium is free of any traces of alkali metal impurities, e.g. sodium metal impurity.
• the object of the present invention to find a novel process which would enable easy and simple preparation and optionally isolation of intermediary novel rosuvastatin salt with organic nitrogen bases, e.g. novel ammonium salts of rosuvastatin, in good quality, and which would enable simple and easy conversion of said novel intermediary compounds to desired commercial amorphous rosuvastatin calcium.
• intermediary novel rosuvastatin salt with organic nitrogen bases e.g. novel ammonium salts of rosuvastatin
• Residual sodium cation may be removed from rosuvastatin calcium by specific method, for instance the rosuvastatin calcium salt can be retreated by vigorous stirring in aqueous suspension, preferably by ultraturrax (Ultra-Turrax ® is brand name of IKA Werke GmbH & Co., Staufen, Germany for dispersion making device with high speed rotation unit).
• ultraturrax Ultra-Turrax ® is brand name of IKA Werke GmbH & Co., Staufen, Germany for dispersion making device with high speed rotation unit.
• the present invention provides the use of aqueous solution of organic nitrogen bases for cleavage of starting C 1 to C 5 alkyl ester of rosuvastatin or rosuvastatin lactone.
• Strong organic nitrogen bases selected from the group consisting of guanidines and amidines can be a method of choice.
• weak bases such as numerous amines if dissolved in water or in the mixtures of water and aprotic solvents, successfully cleft starting rosuvastatin esters if higher temperature is used.
• by elevating temperature to 100 0 C desired product did not neither degrade in considerable extent nor lead to appearance of corresponding amides of rosuvastatin.
• C 1 -C 5 alkyl esters of rosuvastatin or rosuvastatin lactone where alkyl denotes methyl, ethyl, n-proply, /so-propyl, n-butyl, /so-butyl, tert-butyl, amyl or te/f-amyl group, more preferably /ert-alkyl esters, most preferably te/f-butyl ester of rosuvastatin, are cleft in the solutions of organic nitrogen bases and water, optionally containing organic aprotic solvent, e.g. tetrahydrofuran.
• organic aprotic solvent e.g. tetrahydrofuran
• the organic nitrogen base used according to the process of the invention is selected from the group consisting of:
• R 1 , R 2 , R3, R 4 and R 5 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 , R 4 and R 5 independently denotes a C 1 -C 6 alkylene group connection which forms a ring; b) amidines of the formula:
• each of R 1 , R 2 , R3, and R 4 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 , and R 4 independently denotes a C 1 -C 6 alkylene group connection which forms a ring;
• each of R 1 , R 2 and R 3 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 12 alkyl group, unsubstituted or substituted on one or more C-members of the alkyl chain with a radical selected from the group consisting of hydroxy, C 1 -C 6 alkoxy, amino, C 1 -C 6 alkylamino, di-C ⁇ Ce alkylamino, phenyl, pyridinyl, C 1 -C 6 alkylamino or each pair of R 1 , R 2 and R 3 independently denotes C 1 -C 6 alkylene connection which forms a ring;
• each of R 1 , R 2 , R 3 and R 4 independently denotes a hydrogen atom, a straight chain or branched chain C 1 -C 6 alkyl group or cyclic C 1 -C 6 alkyl group or each pair of R 1 , R 2 , R 3 and R 4 independently denotes C 1 -C 6 alkylene group connection which forms a ring;
• R denotes C 1 to C 5 alkyl group and R 1 , R 2 and R 3 denotes radicals as denoted in above formula of amines.
• a preferred organic nitrogen base used from the guanidine group is N,N,N',N'-tetramethylguanidine, from the amidine group 1 ,5- diazabicyclo[4.3.0]non-5-ene (DBN) and 1. ⁇ -diazabicyclof ⁇ AOlundec-y-ene (DBU), from the amine group n-propylamine /so-propylamine, N-methylcyclohexylamine, dicyclohexylamine, N-methyl-iso-propylamine, N,N-di-iso-propylamine, tert-butylamine, tert-octylamine (2,4,4- trimethylpent-2-ylamine), sec-butylamine and diethylamine.
• DBN diazabicyclo[4.3.0]non-5-ene
• DBU 1. ⁇ -diazabicyclof ⁇ AOlundec-y-ene
• the first aspect of the invention are starting Ci to C 5 esters of rosuvastatin or rosuvastatin lactone, hydrolysed with organic nitrogen bases in the presence of water, optionally containing aprotic organic solvent (water content is more than 50 % by volume, preferably more than 75 % by volume).
• the hydrolysis is carried out at temperatures from 0° to 120 0 C.
• strong organic nitrogen bases e.g. guanidines and amidines is preferred temperature from 20° to 70 0 C, more preferred from 40° to 60°.
• weak bases e.g.
• amines is the preferred temperature from 80° to 110 0 C, more preferred from 95° to 105 0 C, most preferred from 98° to 100 0 C.
• the hydrolysis of starting rosuvastatin esters according to the invention by applying volatile amines is carried out in tightly closed vessels at increased pressures.
• a novel intermediary ammonium salts of rosuvastatin may be isolated directly from the hydrolysis mixture by evaporation to dryness, optionally following by treatment with suitable solvent to induce solidification of the corresponding salt, which is further collected, e.g. by filtration.
• suitable solvent e.g. water
• the choice of a solvent for solidification depends on physico-chemical properties of particular salt and can be selected but not limited from nitriles, esters, ethers or hydrocarbons.
• solid isopropylammonium salt of rosuvastatin from acetonitrile and N-methylcyclohexylammonium salt of rosuvastatin from tert-butyl methyl ether are isolated by this manner.
• ammonium salts of rosuvastatin may be converted into rosuvastatin calcium salt without previous isolation of intermediary ammonium salt of rosuvastatin from the solution.
• Aqueous solution of rosuvastatin salt with an appropriate amine obtained after hydrolysis step is optionally washed by water immiscible solvents and further converted with calcium source to precipitate the desired pure amorphous rosuvastatin calcium.
• the water immiscible solvents are selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably more user-friendly solvents, e.g. C 2 -C 5 acetate esters, e.g. ethyl acetate or cyclic hydrocarbons.
• the source of calcium ion is selected from the group consisting of calcium halogenide, preferably calcium chloride, and another calcium source, e.g. calcium nitrate or calcium hydroxide, calcium salt of Ci-C 2O alkanoic acid, preferably calcium palmitate, calcium pivalate or calcium acetate.
• the novel intermediary ammonium salts of rosuvastatin may be prepared from rosuvastatin free acid by the reaction with an appropriate amine.
• the rosuvastatin free acid is prepared from a starting Ci to C 5 ester of rosuvastatin or rosuvastatin lactone by reacting it with a suitable base, e.g. sodium hydroxide, in the presence of an aprotic solvent, optionally diluted with water, and subsequent addition of an acid, e.g. phosphoric acid or hydrochloric acid, to the solution of rosuvastatin sodium salt, thus obtaining rosuvastatin free acid.
• a suitable base e.g. sodium hydroxide
• an aprotic solvent optionally diluted with water
• an acid e.g. phosphoric acid or hydrochloric acid
• the strong inorganic base used in the hydrolysis step may be sodium hydroxide or other alkali metal hydroxide, and the reaction is proceeded in the presence of water or in the presence of a mixture of aprotic solvents and water, such as a mixture of water and tetrahydrofuran, optionally under increased pressure.
• the obtained solution of rosuvastatin alkaline salt is optionally washed by water immiscible solvents selected from the group consisting of esters, ethers, chlorinated hydrocarbons or cyclic hydrocarbons, preferably from more user-friendly solvents such as acetate esters, cyclic hydrocarbons or alkanes, more preferably from ethyl acetate.
• the aqueous phase containing rosuvastatin alkaline salt is subsequently treated by a strong inorganic acid, preferably by phosphoric acid or hydrochloric acid.
• Resulting rosuvastatinic acid (rosuvastatin free acid) is then extracted into water immiscible solvent and the obtained organic phase is converted to the ammonium salt of rosuvastatin by contacting with an appropriate amine.
• an appropriate amine for the purpose of unification of water immiscible organic solvents, if said solvent is used to wash the reaction mixture, the same organic solvent may be used, for example an ester, preferably /so-propyl acetate, for the reaction with an amine.
• the organic extract (above mentioned solution of rosuvastatinic acid in water immiscible solvent, e. g. isopropyl acetate) is treated with an appropriate amine to obtain the corresponding ammonium salt of rosuvastatin.
• an antisolvent selected from other unpolar solvents, such as esters, ethers or hydrocarbons, optionally after concentration of the solution.
• the extracting solvent can be completely removed to isolate the solid ammonium salt of rosuvastatin or if oily further treated with suitable solvent to induce solidification of the corresponding salt, which is finally collected, e.g. by filtration.
• the solvent for the isolation of solid ammonium salt of rosuvastatin in all these alternatives strictly depends on solubility and physical properties of particular salt, but the preferred media are C 2 -C 5 acetate esters and ethers, most preferred /so-propyl acetate and terf-butyl methyl ether.
• N-methylcyclohexylammonium salt (99.6% area by HPLC), cyclohexylammonium salt (99.71 % area); dicyclohexylammonim salt (99.82 % area); pyrrolidinium salt (99.71 % area); piperidinium salt (99.77% area); morpholinium salt (99.51 % area); 1-adamantylammonium salt (99.75% area); tert-octylammonium salt (99.87 % area).
• Some of the isolated solid ammonium salts of rosuvastatin are good crystalline products, and can be isolated substantially pure.
• a characteristic example is tert-octylammonium salt of rosuvastatin, which can be isolated in two different pseudopolymorphs and be because of its purity conveniently used as an analytical standard.
• an anhydrous crystalline form is isolated having diffraction angles in X-ray powder analysis, shown in Table 3, that is the invention is embodied in crystalline tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern characteristic with peaks at 8.0, 15.0, 17.7, 18.4, 18.8, 20.3, and 23.4 ⁇ 0,2 ° 2 ⁇ and/or m.p. around 121 0 C.
• a crystalline monohydrate is isolated having diffraction angles in X-ray powder analysis, shown in Table 4.
• the invention is embodied in crystalline monohydrate of tert-octylammonium salt of rosuvastatin having X-Ray powder diffraction pattern with characteristic peaks at 8.6, 16.5, 18.6, 19.1 , and 19.7 ⁇ 0,2 °2Theta.
• tert-octylammonium salt of rosuvastatin has stable defined structure, therefore is more suitable for use as an analytical standard than amorphous calcium salt with its hygroscopic properties and calcium assay variation.
• the substance can be used as weighing standard compound in HPLC analyses of rosuvastatin.
• the formed ammonium salts of rosuvastatin can be converted into rosuvastatin calcium salt by adding a source of calcium ions to said ammonium salt of rosuvastatin, preferably calcium acetate or calcium hydroxide, using water as a solvent.
• Powder X-ray diffraction spectra of the sample was recorded on Siemens D-5000 with reflexion technique: CuKa radiation, range from 2° to 37° 2Theta, step 0.04° 2Theta, integration time 1 sec.
• the accuracy in the difractograms is believed to be ⁇ 0.2, preferably ⁇ 0.1 2Theta.
• tert-butylammonium salt of rosuvastatin is prepared with essentially the same yield:
• the reactants and water as the solvent are stirred in the autoclave from 98° to 100 0 C for 3 hours.
• the solution formed is then allowed to cool to room temperature, 150 ml of additional demineralized water and 20 ml tetrahydrofurane are added and some very little amount of solid impurities is filtered off.
• the resulting solution is then washed with 2 x 200 ml methylcyclohexane and the aqueous phase is evaporated under reduced pressure at 70 0 C and 15 mbar to remove solvents and the N-methylcyclohexylamine. 50 ml toluene and 70 ml ethyl acetate are added and evaporated again to remove as much water as possible.
• the reactants and solvents are stirred at 50 0 C for 2h.
• the solution formed is then allowed to cool to room temperature and washed twice with 40 ml of methylcyclohexane.
• the aqueous phase is partially evaporated to 25 g of total weight of the residue.
• 0.1 g of charcoal is added to aqueous phase and resulting suspension is stirred for 30 minutes. Charcoal and some solid impurities are filtered off and filtrate is diluted to 30 ml of total volume.
• cyclohexylammonium salt of rosuvastatin 0.45 g, 99.71% area by HPLC;
• dicyclohexylammonim salt of rosuvastatin 0.35 g, 99.82% area;
• piperidinium salt of rosuvastatin 0.28 g, 99.77% area;
• morpholinium salt of rosuvastatin 0.30 g, 99.51% area;
• 1-adamantylammonium salt of rosuvastatin 0.66 g, 99.75% area;
• 16 ml of the filtrate is separated and treated by addition of 0.5 ml of cyclohexylamine in 8 ml of /so-propyl acetate during stirring and rosuvastatin cyclohexylammonium salt precipitate instantaneously as white solid. It is separated by filtration, precipitate is washed on the filter with 10 ml of /so-propyl acetate and dried on the filter yielding 1.34 g of the desired product (99.52% area, HPLC).
• Rosuvastatin tert-butyl ester (27.0 g, 50.2 mmol) is dissolved in 225 ml of a mixture of tetrahydrofuran and water in the ratio of 4:1 by volume.
• the clear solution is warmed to 30 0 C and 8.0 M NaOH (6.75 ml, 54.0 mmol) is added portionwise.
• the reaction mixture is stirred at 30 0 C for 2 hours giving a clear yellow solution.
• tetrahydrofuran is removed completely under the reduced pressure (20 mbar) at 40 0 C.
• the remaining aqueous solution is diluted with water to 225 ml and washed with ethyl acetate (3*90 ml).
• To a vigorously stirring solution of sodium rosuvastatinate is added dropwise HCI 37 % (4.2 ml, 50.2 mmol) at ambient temperature.
• the obtained white emulsion of rosuvastatin free acid is extracted with ethyl acetate (150 ml). After separation from the organic layer aqueous phase is additionally extracted with ethyl acetate (2*50 ml). Organic layers are combined and washed with water (3*30 ml). Then ethyl acetate is removed under reduced pressure (20 mbar) at 40 °C. The residue is dissolved in a minimal amount of acetonitrile and the solvent is rapidly evaporated under reduced pressure (20 mbar) at 40 0 C to give 25.48 g of the solid residue. This solid is then dissolved in acetonitrile (100 ml) to give a clear solution.
• tert-octylamine (6.83 g, 50.2 mmol) over 1 minute at ambient temperature.
• white solid precipitates abundantly from the solution, which cause solidification of the mixture.
• This solid is then treated with 75 ml of a mixture of hexane and acetonitrile in the ratio of 1:2 mixture by volume to give a dense suspension.
• the white precipitate is filtered and dried in vacuum at 40 0 C to give 27.6 g of a white powder. This powder is suspended in hexane (100 ml) and vigorously stirred for 1 hour at ambient temperature.
• Rosuvastatin terf-octylammonium salt (19.5 g) from Example 9 is dissolved in 429 ml of a mixture of acetonitrile and water in the ratio of 10 :1 by volume at ambient temperature. The solution is left to stand at 6 0 C for a few days. The white needles that crystallizes from the mixture are collected by filtration and dried in vacuum at 50 0 C to give 10.48 g (53.7 %) of crystalline rosuvastatin te/f-octylammonium monohydrate salt as white needles.
• the reactants and the solvents are stirred 1.5 hours from 40° to 45°C hydrolysing starting rosuvastatin ester into its potassium salt.
• the clear solution formed is washed twice with 50 ml methylcyclohexane followed by filtration to remove some little amount of solid impurities.
• the filtrate is treated with 100 ml ethyl acetate and 4.3 ml of 85% phosphoric acid forming two layers.
• the upper layer is separated and washed with 20 ml of water.
• To the organic phase is then added 1.0 ml of 85% phosphoric acid and the reaction mixture is heated 5 minutes on the water-bath of the rotavapor at 50 0 C at atmospheric pressure. Then, the solvent is evaporated at reduced pressure.

Landscapes

• Health & Medical Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pharmacology & Pharmacy (AREA)
• General Health & Medical Sciences (AREA)
• Diabetes (AREA)
• Hematology (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Heart & Thoracic Surgery (AREA)
• Cardiology (AREA)
• Obesity (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (7)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37038337

Family Applications (1)

Country Status (8)

Cited By (21)

Families Citing this family (7)

Citations (13)

Family Cites Families (7)

• 2006
  • 2006-06-22 EP EP12171475.2A patent/EP2508514B1/en not_active Not-in-force
  • 2006-06-22 AU AU2006261087A patent/AU2006261087B2/en not_active Ceased
  • 2006-06-22 CA CA2612587A patent/CA2612587C/en not_active Expired - Fee Related
  • 2006-06-22 US US11/922,532 patent/US9150518B2/en not_active Expired - Fee Related
  • 2006-06-22 CN CN201210328276.3A patent/CN102807530B/zh not_active Expired - Fee Related
  • 2006-06-22 JP JP2008517413A patent/JP5146965B2/ja not_active Expired - Fee Related
  • 2006-06-22 CN CN2006800228524A patent/CN101208307B/zh not_active Expired - Fee Related
  • 2006-06-22 WO PCT/EP2006/006007 patent/WO2006136407A1/en not_active Ceased
  • 2006-06-22 EP EP06754501.2A patent/EP1912952B1/en not_active Not-in-force
• 2007
  • 2007-11-19 IL IL187483A patent/IL187483A/en active IP Right Grant

Patent Citations (13)

Also Published As

Similar Documents

Legal Events